ASPI's QLE Signs Binding HALEU Joint Venture With South Africa's Necsa
ASPI is trading near its 52-week low of $2.05 (4.9% above the low).
Summary
ASP Isotopes' wholly-owned Quantum Leap Energy subsidiary signed a binding Heads of Agreement with South Africa's Necsa to form a joint venture for commercial-scale HALEU production at the Pelindaba nuclear site. QLE will hold roughly 80% of the JV and lead operations and capital raising; Necsa contributes site access, safeguards, and licensing support for its ~20% stake, along with an intended EPC arrangement with QLE. The deal converts the November 2024 MOU and February 2026 pre-implementation services contract into a binding commercial framework, and QLE already has HALEU offtake locked up with TerraPower. South Africa's Ministry of Electricity and Energy approved QLE in July 2026 to handle source material and enrichment equipment, and refurbishment of the existing test bench infrastructure is underway. For a company trading near its 52-week low with a modest market cap, a binding framework plus secured offtake is a meaningful de-risking step on the nuclear fuel story, though construction, financing, and full regulatory approvals remain ahead.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — QLE will hold ~80% of the JV and Necsa ~20%, with Necsa contributing site access, safeguards and licensing support and an intended EPC arrangement with QLE.
At the time of this announcement, ASPI was trading at $2.15 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $317.4M. The 52-week trading range was $2.05 to $14.49. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.